{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:17:02Z","timestamp":1788999422560,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial agonist. It is indicated for treatment of schizophrenia and bipolar disorder. This new antipsychotic has low rate of extrapyramidal side effects, metabolic changes and no significant adverse effect on serum prolactin concentration. In addition, it is not associated with significant weight gain like other atypical antipsychotics. As a reason, when other antipsychotics cause these adverse events, it's not uncommon to switch to Aripiprazole. Obsessive compulsive symptoms have been untoward sequel of a few second-generation antipsychotics. Among the second generation antipsychotics Clozapine, Olanzapine, and Risperidone are the most prominent agents associated with these sequelae, according to case reports. More recently, a handful of case reports indicated development of Obsessive-compulsive symptoms with Aripiprazole. We report a case that exhibited similar unexpected adverse effects after administration of Aripiprazole. Keywords: Aripiprazole, Second generation antipsychotics, Obsessive-compulsive symptoms (OCS).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ipj.ipj_182_20","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:53:08Z","timestamp":1640001188000},"page":"158-161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Aripiprazole-induced obsessive\u2013compulsive symptoms"],"prefix":"10.4103","volume":"31","author":[{"given":"Dilshana","family":"Nafisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kakunje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20240829","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"R2-23-20240829","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism","volume":"29","author":"De Bartolomeis","year":"2015","journal-title":"CNS Drugs"},{"key":"R4-23-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200727010-00001","article-title":"Aripiprazole in the treatment of schizophrenia: A consensus report produced by schizophrenia experts in Italy","volume":"27","author":"Cassano","year":"2007","journal-title":"Clin Drug Investig"},{"key":"R5-23-20240829","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R6-23-20240829","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","article-title":"Obsessive-compulsive disorder in schizophrenia: Clinical characteristics and treatment","volume":"18","author":"Poyurovsky","year":"2004","journal-title":"CNS Drugs"},{"key":"R7-23-20240829","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","article-title":"Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: A review of the experimental literature","volume":"16","author":"Fonseka","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"R8-23-20240829","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v66n0107","article-title":"The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients","volume":"66","author":"Connor","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R9-23-20240829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1461145709990976","article-title":"Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting","volume":"13","author":"Kodama","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R10-23-20240829","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/JCP.0b013e31818582de","article-title":"Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?","volume":"28","author":"Schlachetzki","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R11-23-20240829","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00048670903487282","article-title":"Pathological gambling and compulsive eating associated with aripiprazole","volume":"44","author":"Roxanas","year":"2010","journal-title":"Aust N Z J Psychiatry"},{"key":"R12-23-20240829","first-page":"55","article-title":"Quetiapine and obsessive-compulsive symptoms (OCS): Case report and review of atypical antipsychotic-induced OCS","volume":"26","author":"Khullar","year":"2001","journal-title":"J Psychiatry Neurosci"},{"key":"R13-23-20240829","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1503\/jpn.180087","article-title":"Clozapine -induced-Obsessive compulsive symptoms: Mechanisms and Treatment","volume":"44","author":"David","year":"2019","journal-title":"J Psychiatry Neurosci"},{"key":"R14-23-20240829","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13041-020-00621-5","article-title":"Clozapine generates obsessive compulsive disorder-like behavior in mice","volume":"13","author":"Kang","year":"2020","journal-title":"Mol Brain"},{"key":"R15-23-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.9.1.1","article-title":"The role of serotonin in the pathophysiology and treatment of schizophrenia","volume":"9","author":"Abi-Dargham","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R16-23-20240829","first-page":"36","article-title":"Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder?","volume":"51","author":"Goodman","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"R17-23-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl"},{"key":"R18-23-20240829","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"R19-23-20240829","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.jcp.0000270091.32286.0a","article-title":"Aripiprazole-induced obsessive-compulsive disorder: A report of 2 cases","volume":"27","author":"Desarkar","year":"2007","journal-title":"J Clin Psychopharmacol"}],"container-title":["Industrial Psychiatry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_182_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:31Z","timestamp":1787755771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_182_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ipj.ipj_182_20","relation":{},"ISSN":["0972-6748"],"issn-type":[{"value":"0972-6748","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}